# Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study

> **NCT06914908** · PHASE2 · RECRUITING · sponsor: **Sanofi** · enrollment: 64 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** lunsekimig
- **DRUG:** Mometasone furoate nasal spray (MFNS)

## Key facts

- **NCT ID:** NCT06914908
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2031-01-29
- **Final completion:** 2031-01-29
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06914908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06914908, "Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06914908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*